Studies Highlight Both Novel Treatments and Enduring Value of Older Approaches
Retrieved on:
Sunday, December 10, 2023
Human, Woman, ASH, Patient, Research, Infection, Navitoclax, Venetoclax, Cancer, Doctor of Philosophy, Anemia, Mutation, Bone marrow, Food, Progression-free survival, Acute myeloid leukemia, Leukemia, Male, AbbVie, Blood, Diarrhea, Bleeding, Family, Ruxolitinib, Society, San Diego Convention Center, Primary myelofibrosis, Spleen, SAN, Data, PFS, MD Anderson Cancer Center, University, Splenomegaly, Phase, Pain, Cell, B cell, JAK, FCR, Disease, Abdomen, Fatigue, MRD, Weakness, Chronic lymphocytic leukemia, Standard of care, MB, CLL, Lymphoma, Pharmaceutical industry, Medical imaging, Dentistry, Vaccine, Medical device, MD
SAN DIEGO, Dec. 10, 2023 /PRNewswire/ -- Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, and how a powerful, relatively new prognostic tool is helping identify patients who are more or less likely to benefit from both older and newer treatments.
Key Points:
- Two other studies presented in this session spotlight ways in which a novel prognostic tool is demonstrating its value across a range of blood cancers.
- The researchers used MRD to determine how long patients in the targeted-agents group should continue treatment.
- These cells develop into specialized blood cells, such as red and white blood cells and platelets, that also carry the mutation.
- By comparison, progression-free survival (PFS) for patients receiving the standard of care was 76.8% with a death rate of 7%.